 Provention Bio Inc NASDAQ: PRVB announced results from the final analysis of its first-in-human PROVENT study of PRV-101, a polyvalent inactivated coxsackievirus B CVB vaccine candidate. Provention is developing PRV-101 for the prevention of acute CVB infection and its. 